Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer
Status:
Completed
Trial end date:
2017-11-30
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies the side effects and how well pembrolizumab and cryosurgery
work with short term androgen ablation to treat patients with prostate cancer that has
traveled from the original tumor, through the body, and formed a small number of new tumors
in other parts of the body (oligo-metastatic). Cryosurgery, also known as cryoablation or
cryotherapy, kills tumor cells by freezing them. The process also incites an immune response
within the ablated tumor. Giving monoclonal antibodies such as pembrolizumab which enhance a
systemic anti-cancer immune response, may augment the effects of cryosurgery and increase
tumor killing at distant (metastatic) sites.
Phase:
N/A
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins